Dr. Elli Papaemmanuil trained in the UK in population genetics at the Institute of Cancer Research, and in cancer genomics at Wellcome Trust Sanger Center, University of Cambridge, and has led research into the discovery of cancer gene drivers of hematological neoplasms. Dr. Papaemmanuil is a team leader at the Computational Oncology Service, Department of Epidemiology and Biostatistics, at Memorial Sloan Kettering Cancer Center where she is also serving as Associate Director for the Center of Hematological Malignancies. More recently, Dr. Papaemmanuil has developed experimental and analytical methods to support molecular characterization of large patient cohorts and studied the genetic and clinical inter-relationships of leukemias. She currently leads large population genomic profiling studies in myeloid neoplasms (AML, MDS, and MPN) and in acute lymphoblastic leukemia with the aim to characterize how the molecular architecture of the disease and the corresponding clonal relationships determine clinical phenotype and response to therapy, with the aim to deliver patient-tailored diagnostic and risk-stratification algorithms.